Tetrabenazine and Visual acuity reduced - a phase IV clinical study of FDA data

Summary:

Visual acuity reduced is reported as a side effect among people who take Tetrabenazine (tetrabenazine), especially for people who are male, 20-29 old, have been taking the drug for 6 - 12 months also take Fluoxetine, and have Depression.

The phase IV clinical study analyzes which people have Visual acuity reduced when taking Tetrabenazine. It is created by eHealthMe based on reports of 1,576 people who have side effects when taking Tetrabenazine from the FDA, and is updated regularly.

What is Tetrabenazine?

Tetrabenazine has active ingredients of tetrabenazine. eHealthMe is studying from 1,580 Tetrabenazine users. Check the latest studies of Tetrabenazine.

What is Visual acuity reduced?

Visual acuity reduced (reduced clearness of vision) is found to be associated with 1,493 drugs and 1,887 conditions by eHealthMe. Check the latest studies of Visual acuity reduced.

On Jul, 12, 2026

1,576 people reported to have side effects when taking Tetrabenazine.
Among them, 15 people (0.95%) have Visual acuity reduced.

Could Tetrabenazine cause Visual acuity reduced?

Among these 15 people:

How long have people been on Tetrabenazine when they have Visual acuity reduced? *

What is the gender of people who have Visual acuity reduced when taking Tetrabenazine? *

female: 7.14 %
male: 92.86 %

What is the age of people who have Visual acuity reduced when taking Tetrabenazine? *

What are other drugs people take besides Tetrabenazine? *

What are other side effects people have besides Visual acuity reduced? *

Tardive Dyskinesia (a disorder that involves involuntary movements): 14 people, 93.33%
Agitation (state of anxiety or nervous excitement): 13 people, 86.67%
Vision Blurred: 13 people, 86.67%
Drowsiness: 13 people, 86.67%
Extrapyramidal Disorder (involuntary muscle spasms in the face and neck): 13 people, 86.67%
Weight Increased: 2 people, 13.33%
Stomatitis (inflammation of mucous membrane of mouth): 1 person, 6.67%
Gastritis (inflammation of stomach): 1 person, 6.67%
Family Stress: 1 person, 6.67%
Fall: 1 person, 6.67%

What are the existing conditions these people have? *

Depression: 14 people, 93.33%
Psychotic Disorder: 13 people, 86.67%
Extrapyramidal Disorder (involuntary muscle spasms in the face and neck): 13 people, 86.67%
Tongue Disorder (disease of tongue): 1 person, 6.67%
Thyroid Diseases: 1 person, 6.67%
Stress And Anxiety: 1 person, 6.67%
Pain: 1 person, 6.67%
Neuralgia (pain in one or more nerves): 1 person, 6.67%
Hypertonic Bladder (bladder-storage function that causes a sudden urge to urinate): 1 person, 6.67%
High Blood Pressure: 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Tetrabenazine and have Visual acuity reduced?

- Check whether Visual acuity reduced is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tetrabenazine:

Tetrabenazine (1,580 reports)

Browse all side effects of Tetrabenazine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Visual acuity reduced:

Visual acuity reduced (1,493 drugs)

Browse all the conditions that are associated with Visual acuity reduced:

Visual acuity reduced (1,887 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on tetrabenazine (the active ingredients of Tetrabenazine) and Tetrabenazine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.